AU2004246812B8 - Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen - Google Patents

Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen Download PDF

Info

Publication number
AU2004246812B8
AU2004246812B8 AU2004246812A AU2004246812A AU2004246812B8 AU 2004246812 B8 AU2004246812 B8 AU 2004246812B8 AU 2004246812 A AU2004246812 A AU 2004246812A AU 2004246812 A AU2004246812 A AU 2004246812A AU 2004246812 B8 AU2004246812 B8 AU 2004246812B8
Authority
AU
Australia
Prior art keywords
hydroxy tamoxifen
tamoxifen
scar
hydroxy
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004246812A
Other languages
English (en)
Other versions
AU2004246812B2 (en
AU2004246812A1 (en
Inventor
Julius Few
Dana C. Hilt
Andrew R. Palumbo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Besins Healthcare Luxembourg SARL
Northwestern University
Original Assignee
Besins Healthcare Luxembourg SARL
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Luxembourg SARL, Northwestern University filed Critical Besins Healthcare Luxembourg SARL
Publication of AU2004246812A1 publication Critical patent/AU2004246812A1/en
Application granted granted Critical
Publication of AU2004246812B2 publication Critical patent/AU2004246812B2/en
Publication of AU2004246812B8 publication Critical patent/AU2004246812B8/en
Assigned to BESINS HEALTHCARE LUXEMBOURG SARL reassignment BESINS HEALTHCARE LUXEMBOURG SARL Request for Assignment Assignors: ASCEND THERAPEUTICS, INC., NORTHWESTERN UNIVERSITY
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2004246812A 2003-06-09 2004-06-02 Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen Expired AU2004246812B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47661803P 2003-06-09 2003-06-09
US60/476,618 2003-06-09
PCT/EP2004/006583 WO2004110420A1 (en) 2003-06-09 2004-06-02 Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen

Publications (3)

Publication Number Publication Date
AU2004246812A1 AU2004246812A1 (en) 2004-12-23
AU2004246812B2 AU2004246812B2 (en) 2009-12-17
AU2004246812B8 true AU2004246812B8 (en) 2010-01-14

Family

ID=33551623

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004246812A Expired AU2004246812B8 (en) 2003-06-09 2004-06-02 Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen

Country Status (12)

Country Link
US (1) US7767717B2 (enExample)
EP (1) EP1631275B1 (enExample)
JP (1) JP4682129B2 (enExample)
AT (1) ATE393625T1 (enExample)
AU (1) AU2004246812B8 (enExample)
CA (1) CA2528431C (enExample)
DE (1) DE602004013439T2 (enExample)
DK (1) DK1631275T3 (enExample)
ES (1) ES2304610T3 (enExample)
NZ (1) NZ544031A (enExample)
PT (1) PT1631275E (enExample)
WO (1) WO2004110420A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4684655B2 (ja) 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房密度低下
PT1572178E (pt) * 2002-12-18 2006-09-29 Besins Int Lab Tratamento de mastalgia com 4-hidroxi-tamoxifeno
EP1941871B1 (en) * 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
CA2549824C (en) * 2003-12-15 2012-03-13 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
EP1579857A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP1891945A1 (en) * 2006-07-31 2008-02-27 Laboratoires Besins International Treatment and prevention of excessive scarring
CA2659344C (en) * 2006-07-31 2015-03-17 Laboratoires Besins International Treatment and prevention of excessive scarring
AU2008343758A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
AU2008343755A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars
US20140350106A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same
US20140350117A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Topical Scar Treatment Composition and Method of Using Same
CN111163784B (zh) * 2017-09-01 2024-07-26 黄玲惠 用于治疗蟹足肿的药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002130A1 (en) * 1992-07-20 1994-02-03 Massachusetts Institute Of Technology Control of wound scar production with calcium antagonists alone or in a combination with a steroid
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
EP0287690B1 (de) 1987-04-21 1992-09-02 HEUMANN PHARMA GMBH & CO Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
JP3149180B2 (ja) * 1989-07-31 2001-03-26 マサチユセツツ・インスチチユート・オブ・テクノロジー 瘢痕治療のためのカルシウム拮抗薬の使用
TW218849B (enExample) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5720963A (en) 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
AU2513899A (en) * 1997-12-23 1999-07-19 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
US6013270A (en) 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1317921B1 (fr) 2001-12-07 2009-08-19 Besins International Belgique Composition pharmaceutique sous forme de gel ou de solution à base de dihydrotestostérone, son procédé de préparation et ses utilisations
JP4684655B2 (ja) 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房密度低下
PT1572178E (pt) 2002-12-18 2006-09-29 Besins Int Lab Tratamento de mastalgia com 4-hidroxi-tamoxifeno
EP1941871B1 (en) 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002130A1 (en) * 1992-07-20 1994-02-03 Massachusetts Institute Of Technology Control of wound scar production with calcium antagonists alone or in a combination with a steroid
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance

Also Published As

Publication number Publication date
CA2528431C (en) 2012-09-18
WO2004110420A1 (en) 2004-12-23
HK1082203A1 (en) 2006-06-02
AU2004246812B2 (en) 2009-12-17
DE602004013439T2 (de) 2009-06-04
AU2004246812A1 (en) 2004-12-23
EP1631275B1 (en) 2008-04-30
PT1631275E (pt) 2008-08-04
DE602004013439D1 (de) 2008-06-12
DK1631275T3 (da) 2008-08-18
WO2004110420A8 (en) 2005-11-24
ATE393625T1 (de) 2008-05-15
US20050032910A1 (en) 2005-02-10
JP2006527234A (ja) 2006-11-30
CA2528431A1 (en) 2004-12-23
ES2304610T3 (es) 2008-10-16
US7767717B2 (en) 2010-08-03
EP1631275A1 (en) 2006-03-08
NZ544031A (en) 2008-08-29
JP4682129B2 (ja) 2011-05-11

Similar Documents

Publication Publication Date Title
AU2004246812B2 (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
CA2509660C (en) Treatment of mastalgia with 4-hydroxy tamoxifen
US7968532B2 (en) Treatment of gynecomastia with 4-hydroxy tamoxifen
CA2549824C (en) Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
HK1082203B (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
EP1550440A1 (en) Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
MXPA05013435A (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
CA2559748C (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
HK1075403B (en) Treatment of mastalgia with 4-hydroxy tamoxifen
HK1094768B (en) Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 23, NO 49, PAGE(S) 11607 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME ASCEND THERAPEUTICS, INC. AND NORTHWEESTERN UNIVERSITY, APPLICATION NO. 2004246812, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO NORTHWESTERN UNIVERSITY

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BESINS HEALTHCARE LUXEMBOURG SARL

Free format text: FORMER OWNER WAS: ASCEND THERAPEUTICS, INC.; NORTHWESTERN UNIVERSITY

TH Corrigenda

Free format text: IN VOL 27 , NO 24 , PAGE(S) 3735 UNDER THE HEADING ASSIGNMENTS REGISTERED UNDER THE NAME BESINS HEALTHCARE LUXEMBOURG SARL, APPLICATION NO. 2004246812, UNDER INID (71) CORRECT THE PATENTEE NAME TO BESINS HEALTHCARE LUXEMBOURG SARL AND NORTHWESTERN UNIVERSITY

MK14 Patent ceased section 143(a) (annual fees not paid) or expired